



# Antidepressants


Pharmacology and Toxicology  
Central Nervous System Module  
Third Year Medical Students  
Tareq Saleh  
Faculty of Medicine  
The Hashemite University  
Textbook: pp. 128-138

# Mood Disorders

## Major depressive disorder

- 2 weeks of at least **5** of the following symptoms:
  - Depressed mood
  - **Anhedonia** (diminished interest or loss of pleasure in almost all activities)
  - Weight change or appetite disturbance
  - Sleep disturbance (insomnia or hypersomnia)
  - Psychomotor agitation
  - Fatigue or loss of energy,
  - Feelings of worthlessness, diminished ability to think or concentrate;
  - **suicidal ideation** or a suicide attempt

## Mood disorders



Others

## Bipolar disorder

- periods of prolonged depression that alternate with periods of an excessively elevated mood (mania)
- Manic episodes: 1 week of at least **3** of the following symptoms:
  - Grandiosity
  - Diminished need for sleep-excessive talking or pressured speech
  - Racing thoughts or flight of ideas-distractibility
  - Increased level of goal-focused activity at home, at work, or sexually
  - excessive pleasurable activities



# Pathophysiology of Depression

- NOT fully understood.

## Monoamine Theory of Depression:

- norepinephrine (NE), dopamine (DA) & serotonin (5-HT) are neurotransmitters responsible for mood.
- Depression is due to a deficiency in monoamines such as NE and 5-HT.

*Very simplistic----fails to explain the long time course of most antidepressants.*



# Treatment of Depression



# Classes of antidepressants

- Selective serotonin reuptake inhibitors (SSRIs)
- Serotonin/norepinephrine reuptake inhibitors (SNRIs)
- Tricyclic antidepressants (TCAs)
- Atypical antidepressants
- Monoamine oxidase inhibitors (MAOIs)
- Serotonin-Dopamine Activity Modulators (SDAMs)



# Selective Serotonin Reuptake Inhibitors (SSRIs)

## SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)

*Citalopram* CELEXA

*Escitalopram* LEXAPRO

*Fluoxetine* PROZAC

*Fluvoxamine* LUVOX CR

*Paroxetine* PAXIL

*Sertraline* ZOLOFT



# Selective Serotonin Reuptake Inhibitors (SSRIs)

## Mechanism of action


- SSRIs block the reuptake of serotonin → increase its concentrations in the synaptic cleft.

DRUG	UPTAKE INHIBITION	
	Nor-epinephrine	Serotonin
Selective serotonin reuptake inhibitor <i>Fluoxetine</i>	0	++++
Selective serotonin/norepinephrine reuptake inhibitors		
<i>Venlafaxine</i>	++*	++++
<i>Duloxetine</i>	++++	++++
Tricyclic antidepressants		
<i>Imipramine</i>	++++	+++
<i>Nortriptyline</i>	++++	++

# Sites and Mechanisms of CNS Drug Action

NT reuptake:


- Antidepressants





# Selective Serotonin Reuptake Inhibitors (SSRIs)

- Fluoxetine inhibits SERT and interferes with serotonin reuptake.
- This results in increased serotonin availability in the synaptic cleft.






# Selective Serotonin Reuptake Inhibitors (SSRIs)

## Therapeutic uses

- **Depression** (The primary indication)
- Obsessive Compulsive disorder (OCD)
- Panic disorder
- Generalized anxiety disorder
- Social anxiety disorder
- Post-traumatic stress disorder
- Premenstrual dysphoric disorder
- Bulimia Nervosa (*Only fluoxetine*)

# Therapeutic Effect

- SSRIs require 2 weeks to establish a significant alteration in mood (up to 12 weeks and more).





# Selective Serotonin Reuptake Inhibitors (SSRIs)

## Pharmacokinetics

- **Oral.**

- Food has little impact on their absorption (*except for sertraline, for which food increases its absorption*).

- **Metabolized by CYP450 enzyme family**

- fluoxetine differs from the other members of the family in that it has a much longer half life (~50 hours), and the half life of its metabolite can be longer than 10 days.

- **fluoxetine and paroxetine are a potent inhibitors of CYP2D6**

# Selective Serotonin Reuptake Inhibitors (SSRIs)

## Adverse effects

- **Headache, sweating, nausea, vomiting and diarrhea.**
- **Sleep disturbances:**
  - *Paroxetine* and *fluvoxamine* are sedative
  - *Fluoxetine* and *sertraline* are more activating.
- **Sexual dysfunction:** loss of libido, delayed ejaculation, anorgasmia.
  - Very common
  - Could require switching to another family of antidepressants


Nausea



Anxiety



Drowsiness




Insomnia



Sexual dysfunction



Drug interactions





# Selective Serotonin Reuptake Inhibitors (SSRIs)

## Adverse effects

- **Overdose:** “*serotonin syndrome*” especially when used with another MAOi (includes seizures, hyperthermia, muscle rigidity, sweating, myoclonus, ...)
  - **Discontinuation syndrome:** occurs due to abrupt withdrawal (includes headache, malaise, flu-like symptoms, irritability, nervousness, sleep disturbances).
- Particularly by the agents with the shorter half-lives.
- SSRIs should be discontinued gradually.



# Use of SSRIs in Children/Adolescents

- Used with caution.  
[reports of suicidal ideation]
- Fluoxetine and escitalopram are approved to treat childhood depression.
- Fluoxetine, fluvoxamine and sertraline are approved to treat OCD in children



# Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs)



## SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs)

*Desvenlafaxine* PRISTIQ

*Duloxetine* CYMBALTA

*Levomilnacipran* FETZIMA

*Venlafaxine* EFFEXOR




# Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs)



## Mechanism of action

- SNRIs inhibit the reuptake of BOTH serotonin and norepinephrine








# Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs)

## Therapeutic uses

1. **Depression** (when SSRIs are ineffective).
2. **Depression accompanied by a chronic painful condition.**
3. **Neuropathic Pain** (diabetic neuropathy, postherpetic neuralgia, fibromyalgia, etc....)

# Tricyclic Antidepressants (TCAs)



# Tricyclic Antidepressants (TCAs)

## TRICYCLIC ANTIDEPRESSANTS (TCAs)

Tetracyclic →

*Amitriptyline*

*Amoxapine*

*Clomipramine* ANAFRANIL

*Desipramine* NORPRAMIN (the metabolite of imipramine)

*Doxepin* SINEQUAN

*Imipramine* TOFRANIL

Tetracyclic →

*Maprotiline* LUDIOMIL

*Nortriptyline* PAMELOR (the metabolite of amitriptyline)

*Protriptyline* VIVACTIL

*Trimipramine* SURMONTIL



# Tricyclic Antidepressants (TCAs)

## Mechanism of action

- **Inhibition of neurotransmitter (NE and 5-HT ) reuptake:**
- **Receptor antagonism:**
  - TCAs also block serotonergic,  $\alpha$ -adrenergic, histaminic and muscarinic receptors.
  - Amoxapine also blocks 5-HT<sub>2</sub> and dopamine D<sub>2</sub> receptors.

many of the side effects of TCAs result from this non-selective  
receptor antagonism.



# Tricyclic Antidepressants (TCAs)

## Therapeutic uses

- **Moderate to severe depression**
- Panic disorder
- Nocturnal enuresis (bedwetting): Imipramine (largely replaced by desmopressin).
- Migraine and chronic pain conditions: amitriptyline.
- Insomnia: doxepin.

# Tricyclic Antidepressants (TCAs)

## Adverse effects

- **Muscarinic blockade:** blurred vision, xerostomia, urinary retention, sinus tachycardia, constipation and aggravation of angle-closure glaucoma.
- **$\alpha$ -adrenergic blockade:** orthostatic hypotension (imipramine), dizziness and reflex tachycardia.
- **H<sub>1</sub> histamine blockade:** sedation.
- **Overdose:** can be associated with life-threatening cardiac arrhythmias.
- **Sexual dysfunction:** less than SSRIs.

Weight gain



Dry mouth



Constipation




Urinary retention




Blurred vision



Tachycardia



Arrhythmias



Nausea




Drowsiness





**Mutual enhancement:  
hypertension, hyperpyrexia,  
convulsions, and coma**




**MAO  
inhibitors**



**Potentiate effects  
of biogenic amine  
drugs by preventing  
their removal from the  
synaptic cleft**




**Direct-acting  
adrenergic  
drugs**




**Tricyclic  
antidepressants**

**Tricyclic  
antidepressants**



**Ethanol  
Other CNS  
depressants**



**Toxic  
sedation**



**Indirect-acting  
adrenergic  
drugs**



**Block effects of  
indirect-acting  
sympathomimetic  
drugs by preventing  
the drugs from  
reaching their intra-  
cellular sites of action**



# Monoamine Oxidase Inhibitors (MAOi)

## MONOAMINE OXIDASE INHIBITORS (MAOIs)

*Isocarboxazid* MARPLAN

*Phenelzine* NARDIL

*Selegiline* EMSAM

*Tranylcypromine* PARNATE

Non-selective  
(inhibit both  
MAO-A and  
MAO-B)

-Selective for MAO-B

-also used for the treatment of Parkinson's disease.



# Monoamine Oxidase Inhibitors (MAOi)



The use of MAOi is limited (last line) due to the dietary restrictions required while taking these agents, toxicity and drug-drug interaction.



# Monoamine Oxidase Inhibitors (MAOi)

## Mechanism of action:

- MAO enzyme exists in 2 forms:
  - 1- MAO-A: responsible for metabolism of NE and 5-HT.
  - 2- MAO-B: more selective for dopamine (DA) metabolism.
- Most MAOis form stable complexes with the enzyme causing irreversible inactivation.
- **Inhibition of MAO results in ↑ NE + 5-HT + DA**





# Monoamine Oxidase Inhibitors (MAOi)

## **Mechanism of action:**

- The action of MAOi is delayed for several weeks.

MAOi also interfere with hepatic and intestinal isoforms of the enzyme which accounts for their high drug-drug and food-drug interactions.



# Monoamine Oxidase Inhibitors (MAOi)

## Therapeutic uses:

- **Last line for the treatment of depression:** for patients who are unresponsive to SSRIs or TCAs.
- **Atypical depression.**



# Monoamine Oxidase Inhibitors (MAOi)

## **Adverse effects:**

- Orthostatic hypotension, insomnia and convulsions.
- Hepatotoxicity (Phenelzine).
- **Serious food (tyramine-rich) and drug interactions.**




# Monoamine Oxidase Inhibitors (MAOi)

## Tyramine-rich diet and MAOi

- Tyramine is contained in foods such as aged cheese, meats, chicken liver, smoked fish and red wine.
- Tyramine is inactivated by hepatic and intestinal MAOs.
- MAOi interfere with the degradation of dietary tyramine.
- Tyramine accumulation results in the release of large amounts of stored catecholamines → Hypertensive crisis!!!





Copyright © 2006 Nature Publishing Group  
 Nature Reviews | Neuroscience

## MAOIs +

1. Tyramine - rich food	2. Cold Remedies (sympathomimetic)	3. TCAs (↑ CA)	4. Pethidine	5. SSRIs (↑ 5HT)
<p style="text-align: center;">↓</p> <p>Hypertensive crisis <b>(Cheese reaction)</b></p> <p><i>Tyramine in food is metabolized in GIT by MAO-A &amp; MAO-B. MAOIs allow tyramine in tyramine-rich food (old cheese, chicken liver, chocolate) to escape metabolism &amp; release ↑↑↑ amounts of catecholamines from neurons → hypertensive crisis.</i></p>	<p style="text-align: center;">↓</p> <p>Hypertensive Crisis.</p>	<p style="text-align: center;">↓</p> <p>-Hypertension -Hyperthermia -Convulsions</p>	<p style="text-align: center;">↓</p> <p>-Respiratory depression -Hyperthermia -Convulsions</p>	<p style="text-align: center;">↓</p> <p>“<b>Serotonin syndrome</b>”: -Hyperthermia -Convulsions</p>



# Monoamine Oxidase Inhibitors (MAOi)

## Precautions with MAOi

- Patients on nonselective MAOIs should be warned against serious drug interactions and should be given a list of the foods they should avoid.
- Patients on MAOIs should not receive TCAs or SSRIs except after 2 weeks from stopping MAOIs (effect persists for 2 weeks or 6 for fluoxetine).
- Avoid in the elderly because of postural hypotension.



# Atypical antidepressants

## ATYPICAL ANTIDEPRESSANTS

*Bupropion* WELLBUTRIN, ZYBAN

*Mirtazapine* REMERON

*Nefazodone*

*Trazodone* DESYREL

*Vilazodone* VIIBRYD

*Vortioxetine* BRINTELLIX





# Bupropion

- **Mechanism of action:** Weak DA and NE reuptake inhibitor
- **Therapeutic uses:** Depression and smoking cessation (reduces cravings and attenuates nicotine withdrawal symptoms).
- **Adverse effects:** associated with a dose-dependent increased risk for seizures.  
*-----it has a very low incidence of sexual dysfunction.*

# Mirtazapine

- **Mechanism of action:** presynaptic  $\alpha_2$  antagonist and partially due to 5-HT<sub>2</sub> antagonism (enhances serotonin and norepinephrine neurotransmission)
- **Therapeutic uses:**
  - patients intolerant to TCAs or SSRIs.
  - sedating** antidepressant improve insomnia
- **Advantages:** No sexual dysfunction, nausea, anxiety of SSRIs.





Mirtazapine





# Other atypical antidepressants

- **Nefazodone and trazodone:** weak serotonin reuptake inhibitors + 5-HT<sub>2a</sub> antagonists + H<sub>1</sub>-blocking +  $\alpha_1$  antagonism
- **Vilazodone:** serotonin reuptake inhibitor + 5-HT<sub>1a</sub> partial agonism
- **Vortioxetine:** serotonin reuptake inhibitor + 5-HT<sub>1a</sub> agonism + 5-HT<sub>3</sub> and 5-HT<sub>7</sub> antagonism





# Novel therapies

- Brexpiprazole.
- Serotonin-dopamine activity modulator.
- Reading assignment:

<https://www.ncbi.nlm.nih.gov/pubmed/26849053>


# Good news?


## NMDA receptor antagonists

- Esketamine


**PHARMACEUTICAL NEWS** Pharmazoo © Created by Sibel Houba - Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)

### FDA APPROVES NEW NASAL SPRAY MEDICATION FOR TREATMENT-RESISTANT DEPRESSION



**Spravato<sup>™</sup>**  
(esketamine)   
Nasal Spray

**What is SPRAVATO<sup>™</sup>?**  
SPRAVATO<sup>™</sup> is a prescription medicine, used along with an antidepressant taken by mouth, for treatment-resistant depression (TRD) in adults.



**Esketamine**

Esketamine (2S)-2-[(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one] is the S- (more active) enantiomer of ketamine.



# Summary of antidepressants mechanisms of action

## Mechanisms of Increase of Biogenic Amines by Antidepressants

<p style="text-align: center;"><b><u>Amine Pump Inhibitors</u></b></p> <p>Inhibit uptake-I of biogenic amines into neurons resulting in their accumulation in synaptic cleft, potentiating their action at post synaptic receptors.</p>	<p style="text-align: center;"><b><u>MAO Inhibitors</u></b></p> <p>Inhibit metabolism of biogenic amines by MAO enzyme inside nerve endings → ↑stores available for release.</p>	<p style="text-align: center;"><b><u>Presynaptic <math>\alpha_2</math> Blockers</u></b></p> <p>↑ NA release into synaptic cleft by preventing <math>\alpha_2</math> auto-inhibition.</p>
<p style="text-align: center;"><b><u>Members</u></b></p> <p>1. TCAs                      2. TTAD 3. SSRI                      4. NSRI 5. Bupropion</p>	<p style="text-align: center;"><b><u>Members</u></b></p> <p>Tranlycypromine Phenelzine Moclobemide</p>	<p style="text-align: center;"><b><u>Members</u></b></p> <p>Mirtazapine</p>

TCAs: Tricyclic antidepressants

NSRI: Norepinephrine Serotonin Reuptake Inhibitor

TTADs: Tetracyclic antidepressants

SSRIs: Selective Serotonin Reuptake Inhibitor.



Drug class used as first-line therapy of major depressive disorder is SSRIs

Consuming aged cheese and meat is contraindicated while on MAOis for the treatment of depression

The antidepressant that interferes with negative feedback inhibition of norepinephrine release is Mirtazapine

How can you manage major depression in patients on SSRI that are suffering from persistent sexual dysfunction?  
Switch to atypical antidepressants



# Overall Therapeutic Strategy

- The **goal** of initial treatment for depression is symptom remission and restoring baseline functioning.
- The treatment strategy includes *combination of pharmacotherapy and psychotherapy* (based upon randomized trials that found combination treatment was more effective than either of these treatments alone).
- **First line treatment:** SSRIs
- **Alternatives:** second generation antidepressants: SNRIs, atypical antidepressants and serotonin modulators.
- TCAs and MAOis are typically **not** used as initial treatment because of concerns about safety and adverse effects.



# Treatment of Bipolar Disorder



# Drugs Used to Manage Bipolar Disorder

## DRUGS USED TO TREAT MANIA and BIPOLAR DISORDER

*Carbamazepine* TEGRETOL, EQUETRO,  
CARBATROL

*Lamotrigine* LAMICTAL

*Lithium*

*Valproic acid* DEPAKENE, DEPAKOTE



# Lithium

- Used acutely and prophylactically for managing bipolar patients. (effective in 60-80% of patients).
- **Mechanism of action:** Unknown.
- **Pharmacokinetics:**
  - very narrow therapeutic window (highly toxic).
  - entirely eliminated by renal clearance (best choice in patients with hepatic dysfunction)
- **Adverse effects:** headache, xerostomia, polyuria, polydipsia, polyphagia, dermatologic reactions and sedation.
- **Toxicity:** ataxia, slurred speech, confusion, seizures and thyroid dysfunction.





# Treatment of Bipolar Disorder

## Other drugs

- **Antiepileptics:** Carbamazepine, valproic acid and lamotrigine.
- **Antipsychotics:** Chlorpromazine, haloperidol, risperidone, olanzapine, aripiprazole.



- Thank you

- Questions?

Please contact me [tareq@hu.edu.jo](mailto:tareq@hu.edu.jo)